A new age of osteoanabolic therapy? A real-world, two-centre study comparing effects of romosozumab, teriparatide, and antiresorptive therapies for osteoporosis

2026/03/20 by India Richardson-Thornton, Sarah C. Brennan, Livia Liu +6 · 1 voice
Biochemistry, Genetics and Molecular Biology · Medicine · #Bone Metabolism and Diseases #Bone health and osteoporosis research #Bone health and treatments

paper · doi:10.1007/s00198-025-07808-3

crossref issued 2026/03/20 · crossref published 2026/03/20 · crossref published-online 2026/03/20 · openalex created_date 2026/03/20 · openalex publication_date 2026/03/20 · crossref created 2026/03/20 · crossref published-print 2026/04/01 · crossref deposited 2026/05/20 · crossref indexed 2026/05/20 · openalex updated_date 2026/07/23

Discussions

• 🦴 My newest paper out in Osteoporosis International! Australian real-world data on romosozumab vs teriparatide vs antiresorptives. Lumbar spine BMD gains: 11.3% vs 5.0% vs 6.6%. Treatment-naïve pati [bsky, 1 points, 0 comments]